GlassScriptPhysician profile
Stephen R Holloway
NPI 1083792618
$6,859.84
in general payments reported to CMS, 2019-2025
20 companies · $738 in 2025
The $738 reported for 2025 was more than what 86% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $776 · 2020: $279 · 2021: $1,514 · 2022: $1,481 · 2023: $856 · 2024: $1,217 · 2025: $738.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,810.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,810.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $2,291.30 | 2019-2025 | Acuvue |
| Bausch & Lomb Americas INC. | $1,904.11 | 2022-2025 | Infuse, Biotrue One Day, Biotrue |
| Alcon Vision LLC | $589.39 | 2019-2025 | Total30, Precision 1, Tryptyr |
| Sun Pharmaceutical Industries INC. | $532.18 | 2019-2025 | Cequa |
| Coopervision INC. | $353.83 | 2019-2025 | Myday Contact Lens, Clariti Contact Lens, Biofinity Contact Lens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $349.87 | 2019-2021 | |
| Abb Con-Cise Optical Group LLC | $345.74 | 2019-2025 | Spectacle Lenses, Contact Lens |
| Novartis Pharmaceuticals Corporation | $123.96 | 2019-2022 | |
| Oyster Point Pharma, INC. | $57.09 | 2022 | |
| Kala Pharmaceuticals, INC. | $42.59 | 2021-2022 | |
| Carl Zeiss Meditec Ag | $38.80 | 2020 | |
| Shire North American Group INC | $37.47 | 2019 | |
| Abbvie INC. | $34.01 | 2022-2025 | |
| Allergan, INC. | $30.19 | 2021-2022 | |
| Tarsus Pharmaceuticals, INC. | $28.17 | 2025 | Xdemvy |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $23.51 | 2025 | |
| Eyevance Pharmaceuticals LLC | $22.38 | 2022 | |
| Thea Pharma INC. | $21.13 | 2025 | Iyuzeh |
| Harrow Eye, LLC | $20.60 | 2024 | Vevye |
| Horizon Therapeutics Plc | $13.52 | 2023 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Holloway listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.